Expert Interview
Speaking with a KOL about at Protagonist and Takeda's new Phase 3 VERIFY study data of rusfertide, a hepcidin mimetic in development for polycythemia vera.
Ticker(s): PTGX, TAKInstitution: Moffitt Cancer Center
- Hematologist/Oncologist, and Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology.
- Currently manages 200-250 patients with myelofibrosis and is very familiar with the literature to date on Morphosys' pelabresib and noted he "was not involved in the phase 2 MANIFEST, but was involved in MANIFEST-2".
- Primary investigator on a number of myelofibrosis clinical trials including MANIFEST-2 (pelabresib), MOMENTUM (momelotinib), others sponsored by Janssen, Novartis, and Geron, and numerous other clinical trials.
Given rusfertide’s mechanism as a hepcidin mimetic, how do you see its role differing from current cytoreductive agents like hydroxyurea or ruxolitinib? Are there specific PV patient subtypes (e.g., low-risk, phlebotomy-dependent) who might benefit most from rusfertide?
Added By: sara_adminHow do the VERIFY Phase 3 results for rusfertide compare with your expectations, particularly in terms of hematocrit control and phlebotomy independence? Do you believe this data positions rusfertide as a viable frontline or adjunctive therapy in PV?
Added By: sara_adminWhat are your thoughts on the long-term tolerability and safety profile of rusfertide, particularly regarding injection site reactions or iron metabolism effects? Would this impact patient adherence or influence how you sequence therapy?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
